Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeGet StartedBook a Demo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

IDEAYA Biosciences Receives Termination Notice from GSK for Collaboration Agreement

Dec 05, 2025•8 months ago

Contract Type

collaboration_agreement

San FranciscoBiotechnologyHealth Care

Description

On December 4, 2025, GSK communicated its election to terminate the Collaboration, Option and License Agreement with IDEAYA Biosciences. This termination will take effect ninety days after GSK's written notice. During the transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA. The company plans to evaluate its strategic options for these programs in 2026.

Company Information

Company

IDEAYA Biosciences

Location

San Francisco, California, United States

About

IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for IDEAYA Biosciences's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.